Postoperative radiotherapy for non-small cell lung cancer treated with neoadjuvant chemotherapy followed by surgery
10.3760/cma.j.cn113030-20200601-00288
- VernacularTitle:术后放疗在接受新辅助化疗联合手术切除的非小细胞肺癌的应用进展
- Author:
Yongxing BAO
1
;
Zhouguang HUI
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Carcinoma, non-small cell lung/postoperative radiotherapy;
Carcinoma, non-small cell lung/neoadjuvant chemotherapy;
Research progress
- From:
Chinese Journal of Radiation Oncology
2022;31(1):90-96
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant chemotherapy followed by surgery (NCS) is a common therapy pattern of non-small cell lung cancer (NSCLC). However, patients treated with NCS still suffer from relatively high locoregional recurrence. Postoperative radiotherapy (PORT) plays an important role in improving locoregional control, whereas its effect on survival remains controversial. Some studies propose that PORT yields no survival benefits for stage Ⅱ-Ⅲ A(N 2) patients treated with NCS, whereas other researches indicate that PORT can bring survival benefits for high-risk patients. The indications of PORT include R 1/R 2 resection and ypN 2. PORT is recommended with three-dimensional conformal therapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) within the dose range of 50-54 Gy (R 0 resection). The target volume is inconclusive and the irradiation range of mediastinum involving with the metastatic lymph node regions is recommended in many studies. The adverse effects of PORT are acceptable in most studies.Nevertheless, the evidence level of relevant studies is relatively low. These results remain to be clarified by prospective randomized clinical trials.
